Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial, Using Interleukin-2 (IL-2) and Abatacept in Patients with Frontotemporal Disorders

NCT06395038 is registered in ClinicalTrials.gov with The Methodist Hospital Research Institute as lead sponsor.

NCT NCT06395038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06395038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial, Using Interleukin-2 (IL-2) and Abatacept in Patients with Frontotemporal Disorders
Lead sponsor
The Methodist Hospital Research Institute
Phase
Phase 1
Overall status
Unknown status
Start date
May 6, 2024
Completion date
April 30, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

frontotemporal degeneration